Clinical Trial

NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

Study acronym: DUOLife
Recruiting
View on ClinicalTrials.gov →
Summary
This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line (1L) regimens with Carboplatin/Paclitaxel/Durvalumab (CPD) followed by maintenance therapy with durvalumab or durvalumab and olaparib in line with the applicable european summary of product characteristics (SmPC). Additionally, patient-reported outcomes after 1L treatment with CPD will be assessed.
Protocol Amendment History 4 changes
notable Trial sites expanded: 42 -> 49 locations 2026-06-25
notable Trial sites expanded: 33 -> 42 locations 2026-05-13
notable Primary completion pushed: 2028-09-30 -> 2029-03-31 2026-05-13
minor Completion pushed: 2028-09-30 -> 2029-03-31 2026-05-13
Trial Details
NCT Number NCT06890273
Lead Sponsor AstraZeneca
Collaborators: North-Eastern German Society of Gynecological Oncology (NOGGO e.V.)
Conditions Endometrial Cancer
Enrollment 150 participants
Start Date 2025-05-20
Primary Completion 2029-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-24